Global Trends in Stem Cell Therapy Clinical Trials – A 10-Year Retrospective, 2007–2016
Reference Code: GDHC1299EI
Published: June 2017 HealthcareGlobalData 2017. This product is licensed and is not to be photocopied.
1 Table of Contents
1 Table of Contents........ 2
1.1 List of Figures....... 3
2 Introduction.... 4
2.1 Report Scope........ 4
2.2 Methodology........ 4
2.3 Organizations Mentioned . 4
3 Stem Cell Therapy Trial Landscape....... 5
3.1 Introduction......... 5
3.2 Stem Cell Therapy Clinical Trials by Phase and Sponsor Type, 2007–2016.......... 5
3.3 Single-Country and Multinational Stem Cell Therapy Trials, 2007–2016. 8
3.4 Average Size of Stem Cell Therapy Clinical Trials, 2007–2016..... 9
3.5 Stem Cell Therapy Clinical Trials by Therapy Area, 2007–2016.11
3.6 Top Indications for Stem Cell Therapy Clinical Trials, 2007–2016 ..........12
3.7 Stem Cell Therapy Clinical Trials by Status, 2007–2016.14
3.8 Top Sponsors for Stem Cell Therapy Clinical Trials, 2007–201615
3.9 Top Interventions Investigated in Stem Cell Therapy Clinical Trials, 2007–2016...........17
3.10 Stem Cell Therapy Clinical Trials by Country, 2007–2016..........18
4 Summary...... 19
5 About the Authors.... 20
5.1 Associate Analyst, Clinical Trials Database.........20
5.2 Global Director of Databases and Analytics.......20
6 About the Pharmaceutical Clinical Trials Team........... 21
7 About GlobalData ...... 22
7.1 Contact Us..........22
7.2 Disclaimer...........23
Global Trends in Stem Cell Therapy Clinical Trials – A 10-Year Retrospective, 2007–2016
Reference Code: GDHC1299EI
Published: June 2017 HealthcareGlobalData 2017. This product is licensed and is not to be photocopied.
1.1 List of Figures
Figure 1: Stem Cell Therapy Clinical Trials by Phase , 2007–2016 ..... 6
Figure 2: Stem Cell Therapy Clinical Trials by Sponsor Type, 2007–2016 ..... 7
Figure 3: Stem Cell Therapy Single-Country and Multinational Trials, 2007–2016 ... 8
Figure 4: Average Size of Stem Cell Therapy Clinical Trials, 2007–2016 ....... 9
Figure 5: Stem Cell Therapy Clinical Trials by Average Number of Locations, 2007–2016 . 10
Figure 6: Stem Cell Therapy Clinical Trials by Therapy Area and Sponsor Type, 2007-2016 ........... 11
Figure 7: Stem Cell Therapy Clinical Trials for the Top Five Indications by Sponsor Type, 2007–2016 ....... 12
Figure 8: Stem Cell Therapy Clinical Trials for the Top Five Indications by Phase, 2007–2016 ....... 13
Figure 9: Status of Stem Cell Therapy Clinical Trials by Sponsor Type, 2007–201614
Figure 10: Top Industry Sponsors for Stem Cell Therapy Clinical Trials, 2007–2016 .......... 15
Figure 11: Top Non-Industry Sponsors for Stem Cell Therapy Clinical Trials, 2007–2016 .. 16
Figure 12: Top Drugs Investigated in Stem Cell Therapy Clinical Trials, 2007–2016 ........... 17
Figure 13: Stem Cell Therapy Clinical Trials by Country, 2007–2016 .......... 18
Global Trends in Stem Cell Therapy Clinical Trials – A 10-Year Retrospective, 2007–2016
Reference Code: GDHC1299EI
Published: June 2017 HealthcareGlobalData 2017. This product is licensed and is not to be photocopied.
2 Introduction
2.1 Report Scope
This whitepaper provides a review of global clinical trials for stem cell therapy initiated between 2007
and 2016. The data for this review were derived from the Clinical Trials Database of GlobalData’s
Pharma Intelligence Center. The aim of this paper is to provide analyses of the main features of these
trials according to 10-year trends, where relevant.
2.2 Methodology
The clinical trials data used for these analyses were extracted from the Clinical Trials Database of
GlobalData’s Pharma Intelligence Center. The data included global interventional trials (94.9%),
observational trials (5.0%), and one expanded access clinical trial, all of which had an initiation
between January 1, 2007 and December 31, 2016. The Clinical Trials Database of the Pharma
Intelligence Center recorded 584 trials that satisfied the above criteria. The data were analyzed and
segmented by sponsor type, trial phases, single or multinational location, size, therapy area, top
indications, status, leading industry drugs, and trial locations investigated in the trials. Further
analyses were carried out on the dataset to identify the top sponsors, and the top Contract Research
Organizations (CROs) involved.
2.3 Organizations Mentioned
The companies mentioned in this whitepaper include Aderans Research Institute, Anterogen, Celgene,
City of Hope, Great Ormond Steet Hospital, MediPost, Mesoblast, Microbot Medical, Nanfang
Hospital, Neuralstem, Pluristem Therapeutics, Samsung Medical Center, Stempeutics Research,
TiGenix, University of California and Los Angeles, Universiti of Kebangsaan Malaysia, University of
Miami, University of Texas, and US Stem Cell.。